Latest Hotspot

Astellas and PeptiDream enter into collaboration to develop next-generation Protein Degradation Drugs

28 July 2023
3 min read

On July 26, 2023, Astellas and PeptiDream announced that they have entered into a research collaboration and licensing agreement to discover innovative protein degradation drugs for two targets selected by Astellas. Astellas will provide PeptiDream with an advance payment of 3 billion Yen.

PeptiDream is a biopharmaceutical Contract Research Organization (CRO) located in Japan, possessing a proprietary Peptide Discovery Platform System (PDPS) that can efficiently produce a highly diversified library of non-standard peptides for identifying high-efficiency and selective 'hit' peptides, which are then developed into therapies based on peptides, small molecules, or conjugate peptides. Utilizing PDPS technology, the company advances the discovery of peptide drugs, small molecule drugs, and the development of therapeutic and diagnostic drugs using peptide-drug conjugates (PDCs). It has collaborated with numerous multinational pharmaceutical companies, including Eli Lilly, Merck, Roche, Novartis, Johnson & Johnson, and Shionogi. In the agreement reached with Astellas, PeptiDream is eligible to receive up to 206 billion Yen in discovery, development, and commercialization milestone payments for each target. Furthermore, PeptiDream is also eligible to receive single-digit royalty payments on the net sales of any products resulting from the collaboration.

Targeted protein degradation is one of the main focuses of Astellas, and the company has previously reached a cooperation agreement on multiple innovative protein degradation therapies with Cullgen Biotech. On June 15, 2023, Astellas and Cullgen reached a research collaboration and exclusive option agreement to discover multiple innovative protein degradation therapies. According to the agreement, the two companies aim to develop multiple targeted protein degradation therapies by combining Cullgen's targeted protein degradation platform uSMITE with novel E3 ligands and Astellas' drug discovery capabilities. The total amount of this collaboration exceeds 1.9 billion US dollars.

图形用户界面, 应用程序

描述已自动生成

Based on the information disclosed by Synapse (click the card below to access Astellas' indications directly after registration, you can get basic information, pipeline layout, revenue, research funds, investment and financing, etc. for this institution for free), as of July 27, 2023, Astellas has made substantial investments in small molecule drugs and biologics (monoclonal antibodies, adeno-associated virus gene therapy, ADC, cell therapy etc.). Their research and development are focused in areas such as oncology, neurology, endocrinology and metabolism. Looking forward to seeing Astellas' future performance.

图形用户界面, 文本, 应用程序

描述已自动生成

FDA approves Tarsus new drug Xdemvy for the treatment of demodex blepharitis
Latest Hotspot
3 min read
FDA approves Tarsus new drug Xdemvy for the treatment of demodex blepharitis
28 July 2023
On July 26, 2023, Tarsus Pharmaceuticals announced that the U.S. FDA has approved Xdemvy (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis.
Read →
Boehringer Ingelheim & Eli Lilly's SGLT2 inhibitor Empagliflozin obtains new indication approval in the European Union
Latest Hotspot
2 min read
Boehringer Ingelheim & Eli Lilly's SGLT2 inhibitor Empagliflozin obtains new indication approval in the European Union
27 July 2023
Empagliflozin is the first Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor to statistically significantly reduce the risk of hospitalization for any cause compared to a placebo in patients with CKD.
Read →
PRGN-2012 - Therapeutic Vaccine for Recurrent Respiratory Papillomatosis
Drug Insights
4 min read
PRGN-2012 - Therapeutic Vaccine for Recurrent Respiratory Papillomatosis
27 July 2023
PRGN-2012 is a therapeutic vaccine that achieves therapeutic effects through immune stimulation.
Read →
An Overview of Vertex Pharmaceuticals's 97 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
3 min read
An Overview of Vertex Pharmaceuticals's 97 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
27 July 2023
Vertex Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1989 and is headquartered in Massachusetts, United States.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.